Somatic mutations in genes commonly mutated in myeloid neoplasms (eg, DNMT3A, TET2, ASXL1) occur with increasing frequency as a function of age in normal individuals. This
phenomenon has been described as clonal hematopoiesis of indeterminate potential (CHIP).
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Molecular PathologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.Nat Genet. 2012; 44: 1179-1181
- Age-related mutations associated with clonal hematopoietic expansion and malignancies.Nat Med. 2014; 20: 1472-1478
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.Leukemia. 2014; 28: 241-247
- Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.N Engl J Med. 2013; 368: 2059-2074
- Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.N Engl J Med. 2014; 371: 2477-2487
- Age-related clonal hematopoiesis associated with adverse outcomes.N Engl J Med. 2014; 371: 2488-2498
- Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.N Engl J Med. 2017; 377: 111-121
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.Blood. 2015; 126: 9-16
- Genomic classification and prognosis in acute myeloid leukemia.N Engl J Med. 2016; 374: 2209-2221
- Clinical and biological implications of driver mutations in myelodysplastic syndromes.Blood. 2013; 122 ([quiz: 3699]): 3616-3627
- Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.J Hematol Oncol. 2012; 5: 12
- DNA methylation: roles in mammalian development.Nat Rev Genet. 2013; 14: 204-220
- Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.Oncotarget. 2017; 8: 73483-73500
- The origin and evolution of mutations in acute myeloid leukemia.Cell. 2012; 150: 264-278
- Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.Blood. 2015; 126: 2362-2365
- Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.Ann Hematol. 2013; 92: 19-24
- Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.Ann Hematol. 2015; 94: 565-573
- Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.Curr Hematol Malig Rep. 2012; 7: 310-320
- The genetic basis of myelodysplasia and its clinical relevance.Blood. 2013; 122: 4021-4034
- MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.Blood. 2015; 126: 2355-2361
- SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Blood. 2015; 126: 233-241
- Clinical significance of somatic mutation in unexplained blood cytopenia.Blood. 2017; 129: 3371-3378
- Clonal hematopoiesis and evolution to hematopoietic malignancies.Cell Stem Cell. 2018; 22: 157-170
- Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.Leuk Res. 2017; 56: 7-12
- Assessment of minimal residual disease in standard-risk AML.N Engl J Med. 2016; 374: 422-433
- Molecular minimal residual disease in acute myeloid leukemia.N Engl J Med. 2018; 378: 1189-1199
- Clinical effect of point mutations in myelodysplastic syndromes.N Engl J Med. 2011; 364: 2496-2506
- Clinical and genetic predictors of prognosis in myelodysplastic syndromes.Haematologica. 2014; 99: 956-964
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood. 2016; 127: 2391-2405
- Revised international prognostic scoring system for myelodysplastic syndromes.Blood. 2012; 120: 2454-2465
- New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.J Clin Oncol. 2012; 30: 820-829
Article info
Publication history
Published online: October 17, 2018
Footnotes
Disclosure Statement: The author has nothing to disclose.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
